Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1316693

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1316693

Childhood Absence Epilepsy Treatment Market by Drug (Lamotrigine, Valproate), Disease Type (Atypical Absence Seizures, Typical Absence Seizures) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & Online Access - 1 Year (Single User License)
USD 4749
PDF, Excel & Online Access - 1 Year (Up to 5 User License)
USD 5749
PDF, Excel & Online Access - 1 Year (Site License)
USD 6749
PDF, Excel & Online Access - 1 Year (Enterprise User License)
USD 8749

Add to Cart

The Global Childhood Absence Epilepsy Treatment Market is forecasted to grow significantly, with a projected USD 237.76 million in 2023 at a CAGR of 7.41% and expected to reach a staggering USD 392.81 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Childhood Absence Epilepsy Treatment Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Childhood Absence Epilepsy Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Lamotrigine and Valproate. The Valproate is projected to witness significant market share during forecast period.

Based on Disease Type, market is studied across Atypical Absence Seizures and Typical Absence Seizures. The Typical Absence Seizures is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Childhood Absence Epilepsy Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Childhood Absence Epilepsy Treatment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Childhood Absence Epilepsy Treatment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Childhood Absence Epilepsy Treatment Market?

4. What is the competitive strategic window for opportunities in the Global Childhood Absence Epilepsy Treatment Market?

5. What are the technology trends and regulatory frameworks in the Global Childhood Absence Epilepsy Treatment Market?

6. What is the market share of the leading vendors in the Global Childhood Absence Epilepsy Treatment Market?

7. What modes and strategic moves are considered suitable for entering the Global Childhood Absence Epilepsy Treatment Market?

Product Code: MRR-433AB1DC2924

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Childhood Absence Epilepsy Treatment Market, by Drug, 2022 vs 2030
  • 4.3. Childhood Absence Epilepsy Treatment Market, by Disease Type, 2022 vs 2030
  • 4.4. Childhood Absence Epilepsy Treatment Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of epilepsy and seizures in children
      • 5.1.1.2. Government assistance for childhood absence epilepsy
      • 5.1.1.3. Increasing parents awareness about CAE
    • 5.1.2. Restraints
      • 5.1.2.1. Risk associated with side effects of medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research & development activities for novel drug developments
      • 5.1.3.2. Emerging novel treatments for absence seizures
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of efficacious and tolerable initial empirical treatment
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Childhood Absence Epilepsy Treatment Market, by Drug

  • 6.1. Introduction
  • 6.2. Lamotrigine
  • 6.3. Valproate

7. Childhood Absence Epilepsy Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Atypical Absence Seizures
  • 7.3. Typical Absence Seizures

8. Americas Childhood Absence Epilepsy Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Childhood Absence Epilepsy Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Childhood Absence Epilepsy Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
Product Code: MRR-433AB1DC2924

LIST OF FIGURES

  • FIGURE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
  • FIGURE 5. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
  • FIGURE 6. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET DYNAMICS
  • FIGURE 8. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 5. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. VIETNAM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ISRAEL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NORWAY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. POLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SWITZERLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 97. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 98. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET LICENSE & PRICING
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!